Roche cancer drug could lose FDA approval

Follow-up studies of a Roche breast cancer drug have shown that it failed to slow tumour growth or help patients live longer.

This content was published on July 16, 2010

This could lead to the drug Avastin being taken off of the American market, as US government health scientists announced on Friday.

The Food and Drug Administration (FDA) approved Avastin in 2008, basing its decision on early-stage trials.

However, follow-up studies done by Swiss pharmaceutical giant Roche indicate that the drug does not significantly extend lives when compared with chemotherapy alone.

According to the FDA, more recent data showed that patients experienced more side effects like high blood pressure and fatigue.

On Tuesday the FDA will ask a panel of cancer experts to review the study results.

The FDA may ultimately decide to withraw its approval for Avastin, which was Roche's top-selling cancer drug in 2009 -- with global sales of $5.9 million (SFr6.2 million). and agencies

In compliance with the JTI standards

In compliance with the JTI standards

More: SWI certified by the Journalism Trust Initiative

Contributions under this article have been turned off. You can find an overview of ongoing debates with our journalists here. Please join us!

If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at

Sort by

Change your password

Do you really want to delete your profile?

Your subscription could not be saved. Please try again.
Almost finished... We need to confirm your email address. To complete the subscription process, please click the link in the email we just sent you.

Weekly top stories

Keep up to date with the best stories from SWI on a range of topics, straight into your mailbox.


The SBC Privacy Policy provides additional information on how your data is processed.